S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:BLFS

BioLife Solutions - BLFS Price Target & Analyst Ratings

$23.50
-0.30 (-1.26%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$23.37
$24.15
50-Day Range
$16.95
$25.18
52-Week Range
$10.40
$31.11
Volume
279,246 shs
Average Volume
291,090 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.20

BioLife Solutions Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$31.20
32.77% Upside
High Prediction$34.00
Average Prediction$31.20
Low Prediction$29.00
TypeCurrent
1/28/22 to 1/28/23
1 Month Ago
12/29/21 to 12/29/22
3 Months Ago
10/30/21 to 10/30/22
1 Year Ago
1/28/21 to 1/28/22
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$31.20$31.20$31.25$59.86
Predicted Upside32.77% Upside88.47% Upside46.26% Upside28.15% Upside
Get BioLife Solutions Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.


BLFS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLFS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioLife Solutions Stock vs. The Competition

TypeBioLife SolutionsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.46
Consensus RatingBuyBuyHold
Predicted Upside32.77% Upside1,055.16% Upside9.95% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/16/2022Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$31.00+37.23%
8/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$29.00+11.50%
5/17/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$48.00 ➝ $34.00+167.09%
5/12/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason McCarthy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$60.00 ➝ $30.00+184.63%
4/25/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
9/2/2021Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carl Byrnes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$55.00 ➝ $65.00+10.49%
8/13/2021KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Paul Knight
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight$50.00 ➝ $60.00+24.84%
5/20/2021Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
9/22/2020Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$29.00 ➝ $35.00+42.05%
6/4/2020HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ram Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00+7.26%
(Data available from 1/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BLFS Price Target - Frequently Asked Questions

What is BioLife Solutions's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for BioLife Solutions stock is Buy based on the current 1 buy rating for BLFS. The average twelve-month price prediction for BioLife Solutions is $31.20 with a high price target of $34.00 and a low price target of $29.00. Learn more on BLFS's analyst rating history.

Do Wall Street analysts like BioLife Solutions more than its competitors?

Analysts like BioLife Solutions more than other Medical companies. The consensus rating score for BioLife Solutions is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how BLFS compares to other companies.

Does BioLife Solutions's stock price have much upside?

According to analysts, BioLife Solutions's stock has a predicted upside of 88.47% based on their 12-month price targets.

What analysts cover BioLife Solutions?

BioLife Solutions has been rated by Stephens in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:BLFS) was last updated on 1/28/2023 by MarketBeat.com Staff